Biofrontera Past Earnings Performance
Past criteria checks 0/6
Biofrontera has been growing earnings at an average annual rate of 0.06%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 2.2% per year.
Key information
0.06%
Earnings growth rate
4.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 2.2% |
| Return on equity | -1.8% |
| Net Margin | -1.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By Biofrontera AG's (ETR:B8F) 30% Share Price Plunge
Mar 07
We're Keeping An Eye On Biofrontera's (ETR:B8F) Cash Burn Rate
Feb 19Here's Why It's Unlikely That Biofrontera AG's (ETR:B8F) CEO Will See A Pay Rise This Year
Dec 07Does Biofrontera (ETR:B8F) Have A Healthy Balance Sheet?
Jun 08Biofrontera AG (ETR:B8F) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 14Revenue & Expenses BreakdownBeta
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 32 | 0 | 13 | 8 |
| 30 Sep 23 | 29 | -9 | 13 | 8 |
| 30 Jun 23 | 28 | -11 | 13 | 8 |
| 31 Mar 23 | 25 | -20 | 13 | 7 |
| 31 Dec 22 | 26 | -44 | 12 | 7 |
| 30 Sep 22 | 32 | 11 | 18 | 7 |
| 30 Jun 22 | 31 | 10 | 24 | 7 |
| 31 Mar 22 | 30 | 15 | 29 | 7 |
| 31 Dec 21 | 29 | 38 | 34 | 7 |
| 30 Sep 21 | 28 | -16 | 28 | 6 |
| 30 Jun 21 | 27 | -16 | 29 | 5 |
| 31 Mar 21 | 29 | -12 | 26 | 5 |
| 31 Dec 20 | 30 | -13 | 28 | 5 |
| 30 Sep 20 | 33 | -17 | 33 | 5 |
| 30 Jun 20 | 33 | -22 | 37 | 5 |
| 31 Mar 20 | 31 | -10 | 45 | 5 |
| 31 Dec 19 | 31 | -7 | 44 | 5 |
| 30 Sep 19 | 26 | 1 | 44 | 4 |
| 30 Jun 19 | 26 | 8 | 40 | 5 |
| 31 Mar 19 | 23 | -8 | 33 | 5 |
| 31 Dec 18 | 21 | -9 | 31 | 4 |
| 30 Sep 18 | 19 | -14 | 24 | 4 |
| 30 Jun 18 | 16 | -15 | 22 | 4 |
| 31 Mar 18 | 14 | -16 | 21 | 4 |
| 31 Dec 17 | 12 | -16 | 20 | 4 |
| 30 Sep 17 | 11 | -18 | 21 | 5 |
| 30 Jun 17 | 9 | -16 | 17 | 5 |
| 31 Mar 17 | 8 | -14 | 14 | 5 |
| 31 Dec 16 | 6 | -11 | 12 | 5 |
| 30 Sep 16 | 4 | -9 | 9 | 4 |
| 30 Jun 16 | 4 | -7 | 8 | 4 |
| 31 Mar 16 | 4 | -9 | 7 | 6 |
| 31 Dec 15 | 4 | -11 | 7 | 6 |
| 30 Sep 15 | 4 | -12 | 7 | 7 |
| 30 Jun 15 | 3 | -13 | 7 | 7 |
| 31 Mar 15 | 3 | -10 | 7 | 5 |
| 31 Dec 14 | 3 | -11 | 7 | 5 |
| 30 Sep 14 | 3 | -10 | 7 | 4 |
| 30 Jun 14 | 3 | -10 | 7 | 4 |
| 31 Mar 14 | 3 | -9 | 6 | 4 |
| 31 Dec 13 | 3 | -8 | 5 | 3 |
| 30 Sep 13 | 3 | -8 | 5 | 2 |
| 30 Jun 13 | 3 | -7 | 5 | 2 |
Quality Earnings: B8F is currently unprofitable.
Growing Profit Margin: B8F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B8F is unprofitable, but has reduced losses over the past 5 years at a rate of 0.06% per year.
Accelerating Growth: Unable to compare B8F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B8F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: B8F has a negative Return on Equity (-1.85%), as it is currently unprofitable.